| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1155900R |
| P356 | DOI | 10.1371/JOURNAL.PONE.0155900 |
| P932 | PMC publication ID | 4880327 |
| P698 | PubMed publication ID | 27223692 |
| P50 | author | Babu Ramanathan | Q59705972 |
| John Aaskov | Q63092257 | ||
| Chit-Laa Poh | Q72234346 | ||
| Lara Grollo | Q122898782 | ||
| William John Hannan McBride | Q42241671 | ||
| P2093 | author name string | Kristin Kirk | |
| P2860 | cites work | Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. | Q50782689 |
| The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. | Q50993792 | ||
| Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. | Q51935911 | ||
| Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines | Q57607841 | ||
| [Synthetic peptide designs based on immunoactive fragments of the VP1 protein of the foot-and-mouth disease virus strain A22] | Q73481512 | ||
| Gapped BLAST and PSI-BLAST: a new generation of protein database search programs | Q24545170 | ||
| The dengue vaccine pipeline: Implications for the future of dengue control | Q26314683 | ||
| Peptide Vaccine: Progress and Challenges | Q26851329 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes | Q27486235 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus | Q27486788 | ||
| Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens | Q27488243 | ||
| Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization | Q27488408 | ||
| Identification of Continuous Human B-Cell Epitopes in the Envelope Glycoprotein of Dengue Virus Type 3 (DENV-3) | Q27489953 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| Probability-based protein identification by searching sequence databases using mass spectrometry data | Q27860736 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses | Q29616273 | ||
| Dengue | Q29619772 | ||
| MALDI/MS-based epitope mapping of antigens bound to immobilized antibodies | Q30699756 | ||
| Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes. | Q33273910 | ||
| Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice | Q33911897 | ||
| Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay | Q34123956 | ||
| Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial | Q34428943 | ||
| Efficacy of a tetravalent dengue vaccine in children in Latin America. | Q34446032 | ||
| Improved method for predicting linear B-cell epitopes | Q34517062 | ||
| Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes | Q34671059 | ||
| A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins | Q35138111 | ||
| An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques | Q35272502 | ||
| Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice | Q35543857 | ||
| 2013 dengue outbreaks in Singapore and Malaysia caused by different viral strains | Q35692486 | ||
| Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies | Q35758626 | ||
| Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display | Q35764445 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| Determination of protein-derived epitopes by mass spectrometry | Q36279073 | ||
| Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications | Q36795668 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| Immune response to dengue virus and prospects for a vaccine | Q37827145 | ||
| The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease | Q37903445 | ||
| Identifying protective dengue vaccines: guide to mastering an empirical process | Q38125045 | ||
| Enterovirus-Specific Anti-peptide Antibodies | Q38596194 | ||
| Use of synthetic peptides to represent surface-exposed epitopes defined by neutralizing dengue complex- and flavivirus group-reactive monoclonal antibodies on the native dengue type-2 virus envelope glycoprotein | Q38998226 | ||
| Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins | Q38998230 | ||
| Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses | Q39176711 | ||
| Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II. | Q39403339 | ||
| On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes | Q39876628 | ||
| Peptide Inhibitors of Flavivirus Entry Derived from the E Protein Stem | Q40347492 | ||
| Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis | Q40353573 | ||
| A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity | Q40401247 | ||
| Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus | Q40431197 | ||
| Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. | Q40449691 | ||
| Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies | Q40609346 | ||
| T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus | Q40708954 | ||
| Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). | Q40781302 | ||
| Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. | Q46512462 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0155900 | |
| P577 | publication date | 2016-05-25 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine | |
| P478 | volume | 11 |
| Q40038715 | Development of Peptide Vaccines in Dengue. |
| Q27682470 | Genome-wide analyses reveal a highly conserved Dengue virus envelope peptide which is critical for virus viability and antigenic in humans |
| Q59352182 | Identification and immunogenic evaluation of T cell epitopes based on tembusu virus envelope protein in ducks |
| Q66678812 | Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients |
| Q58733184 | Screening and identification of B-cell epitopes within envelope protein of tembusu virus |
Search more.